AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR
Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks
Initiating Phase 2 Study in Early 2023
Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule. This first-in-human study was designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of AMG 133 in people with obesity and without diabetes (NCT04478708). These data will be presented as part of an oral presentation on Saturday, Dec. 3 at the 20th World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) Hybrid Conference.
https://finance.yahoo.com/news/amgen-presents-amg-133-phase-143000480.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.